ClinicalTrials.Veeva

Menu
D

DelRicht Research | Baton Rouge, LA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ruxolitinib
RPT193
Ritlecitinib
Clascoterone
Secukinumab
Ixekizumab
LY3074828
ABP 654
Sofpironium Bromide
PF-06826647

Parent organization

This site is a part of DelRicht Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 26 total trials

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo

Enrolling
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV).Ritlecitinib is studied in patient...

Enrolling
Vitiligo
Drug: Ritlecitinib
Drug: Ritlecitinib 100 mg

This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism...

Enrolling
Chronic Inducible Urticaria
Drug: Oral EVO756

The masseter muscle is one of the muscles in the lower face used for chewing. The prominence of the masseter muscle can appear as a widened lower fac...

Active, not recruiting
Masseter Muscle Prominence
Drug: Placebo
Drug: BOTOX
Locations recently updated

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Enrolling
NonSegmental Vitiligo
Drug: Povorcitinib
Drug: Placebo

The purpose of the study is to see if Clascoterone can help people with male pattern hair loss to recovery and see if the treatment is effective and...

Enrolling
Alopecia, Androgenetic
Drug: Clascoterone 5% solution
Drug: Vehicle solution

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Enrolling
Attention-Deficit/Hyperactivity Disorder
Drug: Placebo
Drug: 100mg SPN-812

The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight receive ix...

Enrolling
Psoriasis
Obesity
Drug: Tirzepatide
Drug: Ixekizumab

A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy

Invitation-only
Focal Epilepsy
Drug: BHV-7000

The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.

Enrolling
Focal Epilepsy
Drug: Placebo
Drug: BHV-7000

The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) for the medication Ameluz® performed with the PDT-lamp BF-Rhod...

Enrolling
Acne Vulgaris
Combination Product: 1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)
Combination Product: 3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CH...

Active, not recruiting
Hand Eczema
Drug: Ruxolitinib cream
Drug: Vehicle

This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical ointment in adult patients with mild to moderate atopic der...

Enrolling
Atopic Dermatitis
Other: Placebo
Drug: YR001 ointment

Trial sponsors

Incyte logo
Lilly logo
Pfizer logo
Biohaven logo
RAPT Therapeutics logo
AbbVie logo
Amgen logo
B
B
C

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems